Roche (RHHBY) News Today $39.25 -0.59 (-1.48%) As of 01/31/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Roche (OTCMKTS:RHHBY) Upgraded at Sanford C. BernsteinSanford C. Bernstein upgraded shares of Roche to a "strong-buy" rating in a research report on Thursday.February 1 at 6:01 AM | marketbeat.comPharma Stock Roundup: SNY and RHHBY's Q4 Earnings & MoreJanuary 31 at 3:26 PM | msn.comRoche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 ProgressJanuary 31 at 1:20 PM | seekingalpha.comRoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTUJanuary 31 at 11:45 AM | globenewswire.comRoche Holding AG (RHHBF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...January 31 at 2:37 AM | gurufocus.comRoche FY24 Core Operating Profit Rises; Sales Up 7% At CERJanuary 30 at 3:41 PM | markets.businessinsider.comRoche targets mid-single digit sales growth in 2025 with robust pipeline momentumJanuary 30 at 3:41 PM | msn.comRoche Holding AG (RHHBY) Q4 2024 Earnings Call TranscriptJanuary 30 at 3:01 PM | seekingalpha.comRoche Holding AG (OTCMKTS:RHHBY) Holdings Decreased by OLD National Bancorp INOLD National Bancorp IN reduced its stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 255,067 shares of the compJanuary 30 at 8:56 AM | marketbeat.comRoche sees high single-digit core profit growth in 2025January 30 at 1:08 AM | reuters.com[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growthJanuary 30 at 1:00 AM | globenewswire.comF. Hoffmann-La Roche Ltd: Change to the Roche Enlarged Corporate Executive CommitteeJanuary 29 at 6:46 AM | finanznachrichten.deGenentech announces INAVO120 study met key secondary endpointJanuary 29 at 6:46 AM | markets.businessinsider.comChange to the Roche Enlarged Corporate Executive CommitteeJanuary 29 at 1:00 AM | globenewswire.comGenentech's Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast CancerJanuary 28, 2025 | businesswire.comRoche's Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancerJanuary 28, 2025 | globenewswire.comRoche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)January 27, 2025 | globenewswire.comRoche gets FDA clearance for STI test panelsJanuary 22, 2025 | msn.comRoche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of careJanuary 22, 2025 | globenewswire.comB-cell Depletion Innovation Research Report 2024: Roche Dominate the Patent Activity in B-cell Depletion Therapy, with a Dip in New Companies Filing Patents in Recent YearsJanuary 17, 2025 | globenewswire.comRoche receives FDA clearance for B-cell lymphoma diagnostic testJanuary 14, 2025 | markets.businessinsider.comDyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene TherapyJanuary 13, 2025 | tmcnet.comRoche's New Test For B-Cell Lymphoma Obtains FDA ClearanceJanuary 13, 2025 | markets.businessinsider.comRoche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphomaJanuary 13, 2025 | prnewswire.comPharma companies welcome new year with 583 drug price hikes so farJanuary 9, 2025 | msn.comRoche's momentum in digital pathology continues with FDA clearance on its high-volume slide scannerJanuary 9, 2025 | prnewswire.comRoche set to finalise $1.5bn Poseida Therapeutics takeoverJanuary 8, 2025 | proactiveinvestors.comF. Hoffmann-La Roche Ltd: Roche purchases shares in tender offer for Poseida Therapeutics, Inc.January 8, 2025 | finanznachrichten.deRoche to close $1.5B acquisition of Poseida TherapeuticsJanuary 8, 2025 | seekingalpha.comRoche to complete acquisition of U.S. biopharma company PoseidaJanuary 8, 2025 | reuters.comRoche purchases shares in tender offer for Poseida Therapeutics, Inc.January 8, 2025 | globenewswire.comRoche Vabysmo Sales Surpassed USD 4 Billion In 2024January 7, 2025 | globenewswire.comRoche Holding AG (OTCMKTS:RHHBY) Shares Acquired by Bard Financial Services Inc.Bard Financial Services Inc. grew its stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 37.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,850 shares of the company's stock after acJanuary 6, 2025 | marketbeat.comRoche Executing Commercially, But R&D Productivity Remains A Work In ProgressJanuary 4, 2025 | seekingalpha.comInnovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug ConjugateJanuary 1, 2025 | prnewswire.comRoche CEO Reassures No Job Cuts Despite Challenges: ReportDecember 30, 2024 | benzinga.comRoche CEO says no plans for job cuts, business healthy, Reuters reportsDecember 30, 2024 | msn.comRoche has no plans for job cuts and business is healthy, CEO saysDecember 29, 2024 | reuters.comRoche (OTCMKTS:RHHBY) Stock Price Passes Below Fifty Day Moving Average - Here's What HappenedRoche (OTCMKTS:RHHBY) Shares Pass Below 50-Day Moving Average - Here's What HappenedDecember 27, 2024 | marketbeat.comRoche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical BenefitsDecember 19, 2024 | benzinga.comRoche, Prothena miss main goal in mid-stage trial for Parkinson’s drugDecember 19, 2024 | msn.comRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s diseaseDecember 19, 2024 | uk.finance.yahoo.comGenentech's Phase IIb Study Of Prasinezumab In Early-Stage Parkinson's Disease Misses Main GoalDecember 19, 2024 | markets.businessinsider.comGenentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's DiseaseDecember 19, 2024 | businesswire.comRoche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's diseaseDecember 19, 2024 | globenewswire.comF. Hoffmann-La Roche Ltd: Roche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solutionDecember 18, 2024 | finanznachrichten.deRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solutionDecember 18, 2024 | globenewswire.comF. Hoffmann-La Roche Ltd: Roche's Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindnessDecember 13, 2024 | finanznachrichten.deRoche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindnessDecember 13, 2024 | finance.yahoo.comRoche Announces Approval Of Vabysmo Prefilled Syringe In The EU - Quick FactsDecember 13, 2024 | markets.businessinsider.com Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address RHHBY Media Mentions By Week RHHBY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RHHBY News Sentiment▼0.400.69▲Average Medical News Sentiment RHHBY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RHHBY Articles This Week▼196▲RHHBY Articles Average Week Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies China Construction Bank News Airbus News EssilorLuxottica Société anonyme News Iberdrola News Atlas Copco News Nintendo News BNP Paribas News Vinci News Compass Group News Bayerische Motoren Werke Aktiengesellschaft News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RHHBY) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
